公开(公告)号：US12138346B2

公开(公告)日：2024-11-12

申请号：US18368097

申请日：2023-09-14

Applicant: LEMONEX INC.

Inventor： Cheolhee Won

IPC: A61K9/16 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/17 ,  A61K38/46 ,  A61K39/395

Abstract: A bioactive substance delivery system includes a bioactive substance comprising nucleic acid, and a bioactive substance carrier comprising a porous silica particle having a plurality of pores with a diameter of 5 nm to 100 nm, and having not less than 24 hours at which a ratio of absorbance is ½. The porous silica particles may be positively charged inside the pore at neutral pH.

公开(公告)号：US10809196B2

公开(公告)日：2020-10-20

申请号：US15765409

申请日：2016-06-15

Applicant: LEMONEX INC.

Inventor： Cheolhee Won ,  Dal-Hee Min

IPC: G01N33/53 ,  C12Q1/70 ,  G01N33/533 ,  G01N21/64 ,  C12N15/115 ,  G01N33/58 ,  C12Q1/6888 ,  C12Q1/6818 ,  C08B37/02 ,  C08B37/08 ,  C12N1/20 ,  G01N33/574 ,  A61K49/00 ,  B82Y30/00

Abstract: A quencher containing water-soluble polymer-conjugated nanomaterial effectively quenches the fluorescence of a fluorescent material-conjugated probe. In addition, a composition including the quencher and a fluorescent material-conjugated probe can detect a target material existing at a low concentration, and thus can be favorably used as a composition or kit for providing information necessary for the detection of a biomaterial or the diagnosis of a disease.

公开(公告)号：US11793757B2

公开(公告)日：2023-10-24

申请号：US17399320

申请日：2021-08-11

Applicant: LEMONEX INC.

Inventor： Cheolhee Won

IPC: A61K9/16 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/17 ,  A61K38/46 ,  A61K39/395

CPC classification number: A61K9/1611 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/1758 ,  A61K38/465 ,  A61K39/395

Abstract: A porous silica particles according to an embodiment of the present disclosure includes a plurality of pores with a diameter of 5 nm to 100 nm. The porous silica particles have particular physical properties, can deliver all various drugs by a supported amount in a sustained manner, and can be parenterally administered.

公开(公告)号：US11786469B2

公开(公告)日：2023-10-17

申请号：US15328121

申请日：2015-03-31

Applicant: LEMONEX INC. ,  Cheolhee Won

Inventor： Cheolhee Won

IPC: A61K9/14 ,  A61K47/02 ,  A61K39/395 ,  A61K47/40 ,  A61K9/16 ,  B82Y5/00

CPC classification number: A61K9/143 ,  A61K9/145 ,  A61K9/16 ,  A61K39/395 ,  A61K47/02 ,  A61K47/40 ,  B82Y5/00

Abstract: A composition for delivering a bioactive material include a porous silica nanoparticle containing pores with an average pore diameter ranging from 1 nm to 100 nm, at least one of (i) a functional group which binds to the pore surface of the porous silica nanoparticle and gives the pore surface a negative charge or a positive charge, (ii) a ligand which binds to the pore surface of the porous silica nanoparticle and specifically binds to the bioactive material, and (iii) a combination of the functional group and the ligand, and a bioactive material having a size to be accommodated within the pores of the porous silica nanoparticle, the bioactive material bound to said at least one of the functional group and the ligand bound to the pore surface of the mesoporous silica nanoparticle and accommodated within the pores of the porous silica nanoparticle.

公开(公告)号：US12076336B2

公开(公告)日：2024-09-03

申请号：US17536880

申请日：2021-11-29

Applicant: LEMONEX INC.

Inventor： Cheolhee Won

IPC: C07H21/02 ,  A61K31/713 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K31/713 ,  A61P35/00 ,  C12N15/113 ,  C12N15/1135 ,  C12N2310/14

Abstract: The present invention provides siRNA or dsRNA, which can effectively inhibit the expression of three highly expressed markers in liver cancer, and a pharmaceutical composition including the same can obtain excellent effects of preventing or treating liver cancer through RNAi. A pharmaceutical composition for preventing or treating liver cancer according to an embodiment of the present invention includes at least one of siRNA which includes a sense RNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 5 to 157, and an antisense RNA having a complementary sequence thereto and dsRNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 158 to 310.

公开(公告)号：US11129796B2

公开(公告)日：2021-09-28

申请号：US16483830

申请日：2018-02-06

Applicant: LEMONEX INC.

Inventor： Cheolhee Won

IPC: A61K9/16 ,  A61K31/704 ,  A61K31/4745 ,  A61K31/44 ,  A61K31/203 ,  A61K38/17 ,  A61K31/713 ,  A61K31/711 ,  A61K39/395 ,  A61K38/46

Abstract: A bioactive substance carrier includes a bioactive substance and porous silica particles supporting the bioactive substance and having a plurality of pores with a diameter of 5 nm to 100 nm. The porous silica particles have particular physical properties, can deliver all various drugs by a supported amount in a sustained manner, and can be parenterally administered.

公开(公告)号：US11779582B2

公开(公告)日：2023-10-10

申请号：US16476220

申请日：2018-01-08

Applicant: LEMONEX INC.

Inventor： Jae Ho Lee ,  Cheolhee Won

IPC: A61K31/506 ,  A23L33/10 ,  A61P35/04 ,  A61K33/243 ,  A61K31/165 ,  A61K31/337 ,  A61K31/343 ,  A61K31/475

CPC classification number: A61K31/506 ,  A23L33/10 ,  A61K31/165 ,  A61K31/337 ,  A61K31/343 ,  A61K31/475 ,  A61K33/243 ,  A61P35/04 ,  A23V2002/00

Abstract: A method for treatment of cancer selected from the group consisting of metastatic ovarian cancer, endometrial cancer, and breast cancer includes administering a composition comprising a compound represented by Formula 1, a pharmaceutically acceptable salt thereof to a subject in need thereof: The composition can efficiently kill cancer cells present in a spheroid form, thereby being usefully applied as novel medicament for metastatic ovarian cancer, endometrial cancer or breast cancer.

公开(公告)号：US11530132B2

公开(公告)日：2022-12-20

申请号：US16122872

申请日：2018-09-05

Applicant: LEMONEX INC.

Inventor： Dal-Hee Min ,  Cheolhee Won ,  Sejin Park ,  Seongchan Kim

IPC: C01B37/02 ,  C12N5/00 ,  A61K9/50 ,  B01J13/02 ,  B82Y5/00 ,  A61K9/51 ,  C12N5/077 ,  A61K31/711 ,  A61K45/06 ,  A61K31/352 ,  A61K47/69 ,  A61K31/196 ,  C12N5/079 ,  A61K31/706 ,  A61K31/437 ,  C12N5/071 ,  A61K35/12

Abstract: A composition includes porous silica particles to carry a cell fate modulating factor therein. A method for modulating cell fate includes treating various cells with the composition. The cell fate modulating factor is delivered to a stable target receptor, toxicity to subject cells for delivery may be reduced, a fate of the subject cells can be controlled through sustained release of at least 99 wt. % of the cell fate modulating factor.